Application of L-citrulline in preparation of medicine for preventing or treating tuberculosis
L-citrulline significantly reduces bacterial load and prolongs survival time in the treatment of tuberculosis, solving the drug resistance problem in existing technologies, providing an innovative strategy based on host metabolic regulation, enhancing host immune defense, and shortening the treatment course.
Patent Information
- Application Number
- CN202510966086.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-14
- Publication Date
- 2025-09-16
AI Technical Summary
Existing tuberculosis treatment regimens rely on antibiotics, which have drug resistance problems and lack innovative strategies based on host metabolic regulation. How to use endogenous metabolites to regulate host immune defense to reduce bacterial load has become the key to breaking through the drug resistance dilemma.
L-citrulline is used as an endogenous amino acid metabolite, and its significant effect in anti-tuberculosis treatment is verified through a zebrafish-marimolecular mycobacterium infection model, which significantly reduces bacterial load and prolongs survival time. The drug form includes solution, injection or oral preparation, which may contain a pharmaceutically acceptable carrier.
L-citrulline significantly reduces the bacterial load of Mycobacterium marinum, prolongs the survival time of zebrafish, exerts anti-inflammatory effects, and provides a new metabolite intervention strategy for anti-tuberculosis treatment, enhances host immune defense, reduces the survival and spread of Mycobacterium tuberculosis, and shortens the course of treatment.